☰

Brian Cameron, M.D. - Publications

Affiliations: 
McMaster University hospital, Hamilton ON 
Tree Info Similar researchers PubMed Report error

18 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Holland CJ, Crean RM, Pentier JM, de Wet B, Lloyd A, Srikannathasan V, Lissin N, Lloyd KA, Blicher TH, Conroy PJ, Hock M, Pengelly RJ, Spinner TE, Cameron B, Potter EA, et al. Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA. The Journal of Clinical Investigation. PMID 32310221 DOI: 10.1172/Jci130562  0.443
2016 Bossi G, Kenefeck R, Boudousquie CC, Harper J, Dukes J, Liddy N, Paston S, Mahon T, Molloy P, Sami M, Baston E, Cameron B, Vuidepot A, Hassan N, Jakobsen BK. Abstract 4873: ImmTACs re-direct the immune system efficiently to eradicate cancer Cancer Research. 76: 4873-4873. DOI: 10.1158/1538-7445.Am2016-4873  0.48
2016 Knox A, Chester F, Bianchi F, Bailey S, Bouard L, Liddy N, Bossi G, Harper J, Dukes J, Paston S, Mahon T, Gavarret J, Molloy P, Sami M, Baston E, ... Cameron B, et al. Abstract 4872: Developing high affinity, soluble T cell receptors for the treatment of cancer Cancer Research. 76: 4872-4872. DOI: 10.1158/1538-7445.Am2016-4872  0.494
2015 Donnellan Z, Bossi G, Harper J, Dukes J, Liddy N, Paston S, Mahon T, Molloy P, Sami M, Baston E, Cameron B, Johnson A, Vuidepot A, Hassan N, Jakobsen B. ImmTACs: bi-specific TCR-anti-CD3 fusions for targeted tumour killing Journal For Immunotherapy of Cancer. 3: 299. DOI: 10.1186/2051-1426-3-S2-P299  0.439
2014 Bossi G, Baker D, Adams K, Harper J, Dukes J, Liddy N, Paston S, McGrath Y, Mahon T, Molloy P, Sami M, Baston E, Cameron B, Johnson A, Vuidepot A, et al. Abstract 670: ImmTACs: Bi-specific TCR-anti-CD3 fusions for potent re-directed killing of cancer cells Cancer Research. 74: 670-670. DOI: 10.1158/1538-7445.Am2014-670  0.49
2014 Hassan NJ, Bossi G, Baker D, Adams K, Harper J, Dukes J, Liddy N, Paston S, McGrath Y, Mahon T, Molloy P, Sami M, Baston E, Cameron B, Johnson A, et al. Abstract 2900: IMCgp100: A novel bi-specific biologic for the treatment of malignant melanoma Cancer Research. 74: 2900-2900. DOI: 10.1158/1538-7445.Am2014-2900  0.469
2013 Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, Bossi G, Vuidepot A, Powlesland AS, Legg A, Adams KJ, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Science Translational Medicine. 5: 197ra103. PMID 23926201 DOI: 10.1126/Scitranslmed.3006034  0.314
2012 Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K, Gostick E, Sewell AK, Lissin NM, Harwood NE, Molloy PE, ... ... Cameron BJ, et al. Monoclonal TCR-redirected tumor cell killing. Nature Medicine. 18: 980-7. PMID 22561687 DOI: 10.1038/Nm.2764  0.387
2012 Hassan NJ, Baker D, Harper J, Adams K, Bossi G, Liddy N, Buisson S, Paston S, Gavarret J, Bianchi F, Baston E, Legg A, Ashfield R, McGrath Y, Li Y, ... ... Cameron B, et al. Abstract 3528: IMCmage1: A novel bi-specific biologic re-directing T cells to kill MAGE-A3/A6 presenting cancers Cancer Research. 72: 3528-3528. DOI: 10.1158/1538-7445.Am2012-3528  0.466
2012 Hassan NJ, Adams K, Bossi G, Harper J, Buisson S, Paston S, Liddy N, Ashfield R, Gavarret J, Bianchi F, Baston E, Baker D, Ladell K, Sewell A, Li Y, ... Cameron B, et al. Abstract 3525: IMCgp100: A novel bi-specific biologic for the treatment of malignant melanoma Cancer Research. 72: 3525-3525. DOI: 10.1158/1538-7445.Am2012-3525  0.472
2011 Harper JV, Hassan NJ, Liddy N, Mahon T, Bossi G, Adams K, Gavarret J, Bianchi F, Lissin N, Molloy P, Li Y, Pumphrey N, Cameron B, Sami M, Baston E, et al. Abstract 4744: Soluble, high affinity TCRs fused to anti-CD3 redirect T cells to kill cancer cells presenting MAGE-A3 and NY-ESO antigens Cancer Research. 71: 4744-4744. DOI: 10.1158/1538-7445.Am2011-4744  0.487
2011 Paston SJ, Ashfield R, Liddy N, Bossi G, Adams K, McCormack E, Lissina A, Mahon T, Hassan N, Gavarret J, Bianchi F, Pumphrey N, Ladell K, Gostick E, Sewell AK, ... ... Cameron B, et al. Abstract 1787: ImmTACs: Bi-functional reagents for redirected tumour cell killing Cancer Research. 71: 1787-1787. DOI: 10.1158/1538-7445.Am2011-1787  0.49
2010 Moysey RK, Li Y, Paston SJ, Baston EE, Sami MS, Cameron BJ, Gavarret J, Todorov P, Vuidepot A, Dunn SM, Pumphrey NJ, Adams KJ, Yuan F, Dennis RE, Sutton DH, et al. High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation. Protein & Cell. 1: 1118-27. PMID 21213105 DOI: 10.1007/s13238-010-0144-5  0.302
2010 Hassan NJ, Liddy N, Mahon T, Bossi G, Adams K, Gavarret J, Bianchi F, Lissin N, Molloy P, Li Y, Pumphrey N, Cameron B, Sami M, Baston E, Harper J, et al. Abstract 5616: Soluble, high affinity TCRs fused to anti-CD3 redirect T cells to kill cancer cells presenting MAGE-A3 and NY-ESO antigens Cancer Research. 70: 5616-5616. DOI: 10.1158/1538-7445.Am10-5616  0.487
2008 Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, Carroll RG, Milicic A, Mahon T, Sutton DH, Laugel B, Moysey R, Cameron BJ, Vuidepot A, Purbhoo MA, Cole DK, et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nature Medicine. 14: 1390-5. PMID 18997777 DOI: 10.1038/Nm.1779  0.307
2007 Purbhoo MA, Li Y, Sutton DH, Brewer JE, Gostick E, Bossi G, Laugel B, Moysey R, Baston E, Liddy N, Cameron B, Bennett AD, Ashfield R, Milicic A, Price DA, et al. The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. Molecular Cancer Therapeutics. 6: 2081-91. PMID 17620437 DOI: 10.1158/1535-7163.Mct-07-0092  0.406
2007 Ashfield R, Sutton D, Bossi G, Brewer J, Purbhoo M, Dennis R, Karbach J, Mahon T, Cameron B, Jakobsen B. High Affinity T Cell Receptors as Therapeutic Agents Clinical Immunology. 123. DOI: 10.1016/J.Clim.2007.03.190  0.338
2006 Purbhoo MA, Sutton DH, Brewer JE, Mullings RE, Hill ME, Mahon TM, Karbach J, Jäger E, Cameron BJ, Lissin N, Vyas P, Chen JL, Cerundolo V, Jakobsen BK. Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. Journal of Immunology (Baltimore, Md. : 1950). 176: 7308-16. PMID 16751374 DOI: 10.4049/Jimmunol.176.12.7308  0.343
Show low-probability matches.